These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35285351)

  • 21. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.
    Heemskerk D; Day J; Chau TT; Dung NH; Yen NT; Bang ND; Merson L; Olliaro P; Pouplin T; Caws M; Wolbers M; Farrar J
    Trials; 2011 Feb; 12():25. PubMed ID: 21288325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensified antibiotic treatment of tuberculosis meningitis.
    Cresswell FV; Te Brake L; Atherton R; Ruslami R; Dooley KE; Aarnoutse R; Van Crevel R
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):267-288. PubMed ID: 30474434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial.
    Garcia-Prats AJ; Svensson EM; Winckler J; Draper HR; Fairlie L; van der Laan LE; Masenya M; Schaaf HS; Wiesner L; Norman J; Aarnoutse RE; Karlsson MO; Denti P; Hesseling AC
    J Antimicrob Chemother; 2021 Nov; 76(12):3237-3246. PubMed ID: 34529779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Sohn H; Schiller I; Kloda LA; Boehme CC; Pai M; Dendukuri N
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009593. PubMed ID: 23440842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
    Justine M; Yeconia A; Nicodemu I; Augustino D; Gratz J; Mduma E; Heysell SK; Kivuyo S; Mfinanga S; Peloquin CA; Zagurski T; Kibiki GS; Mmbaga B; Houpt ER; Thomas TA
    J Pediatric Infect Dis Soc; 2020 Feb; 9(1):14-20. PubMed ID: 30395239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.
    Zhang C; McIlleron H; Ren Y; van der Walt JS; Karlsson MO; Simonsson US; Denti P
    Antivir Ther; 2012; 17(1):25-33. PubMed ID: 22267466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.
    Svensson RJ; Niward K; Davies Forsman L; Bruchfeld J; Paues J; Eliasson E; Schön T; Simonsson USH
    Br J Clin Pharmacol; 2019 Oct; 85(10):2341-2350. PubMed ID: 31269277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings.
    Semvua HH; Kibiki GS; Kisanga ER; Boeree MJ; Burger DM; Aarnoutse R
    Ther Drug Monit; 2015 Feb; 37(1):22-32. PubMed ID: 24943062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment.
    Khadka P; Dummer J; Hill PC; Das SC
    Int J Pharm; 2018 Sep; 548(1):244-254. PubMed ID: 29983396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the Diagnosis and Management of Tubercular Meningitis in Children.
    Bhasin H; Goyal M; Sharma S
    Indian J Pediatr; 2020 Jan; 87(1):26-33. PubMed ID: 31802325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Srivastava S; Bendet P; Koeuth T; Bhavnani SM; Ambrose PG; Smythe W; McIlleron H; Thwaites G; Gumusboga M; Van Deun A; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S274-S283. PubMed ID: 30496459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis.
    Te Brake L; Dian S; Ganiem AR; Ruesen C; Burger D; Donders R; Ruslami R; van Crevel R; Aarnoutse R
    Int J Antimicrob Agents; 2015 May; 45(5):496-503. PubMed ID: 25703312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients.
    Mukonzo JK; Kengo A; Kutesa B; Nanzigu S; Pohanka A; McHugh TD; Zumla A; Aklillu E
    Trans R Soc Trop Med Hyg; 2020 Feb; 114(2):107-114. PubMed ID: 31789383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid, and Brain Extracellular Fluid in South African Children with Tuberculous Meningitis.
    Abdelgawad N; Tshavhungwe MP; Rohlwink U; McIlleron H; Abdelwahab MT; Wiesner L; Castel S; Steele C; Enslin JN; Thango NS; Denti P; Figaji A
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0147422. PubMed ID: 36815838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective Analysis.
    Nair SA; Raizada N; Sachdeva KS; Denkinger C; Schumacher S; Dewan P; Kulsange S; Boehme C; Paramsivan CN; Arinaminpathy N
    PLoS One; 2016; 11(2):e0150054. PubMed ID: 26918818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.